CYP2C19 and pediatric adverse events during citalopram, escitalopram and sertraline treatment /
This retrospective cohort study demonstrates that extrapolation of adult pharmacogenetic guidelines for sertraline, escitalopram, and citalopram and CYP2C19 is not appropriate for pediatric patients.
| Other Authors: | |
|---|---|
| Format: | Video |
| Language: | English |
| Language Notes: | In English. |
| Published: |
Itasca, IL :
American Academy of Pediatrics,
2020.
|
| Series: | Academic Video Online
|
| Subjects: | |
| Online Access: | Connect to this streaming video (Alexander Street Press) |
| Summary: | This retrospective cohort study demonstrates that extrapolation of adult pharmacogenetic guidelines for sertraline, escitalopram, and citalopram and CYP2C19 is not appropriate for pediatric patients. |
|---|---|
| Item Description: | Title from resource description page (viewed August 20, 2021). |
| Physical Description: | 1 online resource (5 minutes) |
| Playing Time: | 00:04:17 |